Proteomics Markers Prognostic for Outcome of Chronic Lymphocytic Leukemia Patients Under Treatment: Results From the Hovon-109 Study

Hematological Oncology - United Kingdom
doi 10.1002/hon.25_2630
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Related search

Gene Mutations and Treatment Outcome in Chronic Lymphocytic Leukemia: Results From the CLL8 Trial

Blood
BiochemistryImmunologyCell BiologyHematology
2014English

Proteomics Exploration of Chronic Lymphocytic Leukemia

Novel Approaches in Cancer Study
2019English

Idelalisib for the Treatment of Chronic Lymphocytic Leukemia

ISRN Oncology
2014English

Chronic Lymphocytic Leukemia and Prognostic Models: A Bridge Between Clinical and Biological Markers

American Journal of Hematology
Hematology
2017English

Molecular Genetic Studies on Chronic Lymphocytic Leukemia and Acute Myeloid Leukemia - With Focus on Prognostic Markers

2014English

Prognostic Role of Translocator Protein and Oxidative Stress Markers in Chronic Lymphocytic Leukemia Patients Treated With Bendamustine Plus Rituximab

Oncology Letters
Cancer ResearchOncology
2014English

Profile of Obinutuzumab for the Treatment of Patients With Previously Untreated Chronic Lymphocytic Leukemia

OncoTargets and Therapy
OncologyPharmacology
2015English

Ofatumumab Monotherapy in Fludarabine-Refractory Chronic Lymphocytic Leukemia: Final Results From a Pivotal Study

Haematologica
Hematology
2015English

Treatment of Patients With Chronic Lymphocytic Leukemia With 17p Deletion: The Saga Continues

Leukemia and Lymphoma
Cancer ResearchOncologyHematology
2011English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy